Delivery Order SPE2DB20D3103-SPE2DB23FP8L2

Award Date 9/22/23
Potential Completion Date 9/25/23
Potential Value $2.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,049.83 firm-fixed-price delivery order is for the supply of RYTARY ER 36.25 MG-145 MG capsules, a medication used to treat Parkinson's disease. The contract has an ultimate completion date of April 5, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,678.74, is for the delivery of RYTARY ER 36.25 MG-145 MG capsules. The contract has a firm fixed price and an ultimate completion date of January 22, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $13,748.54, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RYTARY ER 36.25 MG-145 MG capsules, a prescription drug. The contract is a Firm Fixed Price Delivery Order that runs through December 11, 2024. The award indicates that no set-aside designation was used. In addition to this specific contract, AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,985.36 firm fixed-price delivery order covers the supply of RYTARY ER 36.25 MG-145 MG capsules in 100-count packages. The contract has an ultimate completion date of January 8, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $20,237.14, is for the delivery of RYTARY ER 23.75 MG-95 MG capsules, a medication used in the treatment of Parkinson's disease. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of April 2, 2025. This award is not associated with a set-aside designation....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $12,527.63, is a delivery order contract for the pharmaceutical product RYTARY ER 36.25 MG-145 MG capsules. The contract has a firm fixed price pricing type and runs through February 4, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
The U.S. Defense Logistics Agency (DLA) awarded a $1,272.84 firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide RYTARY ER 36.25 MG-145 MG capsules. This contract has an ultimate completion date of May 2, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,187.74, is for the delivery of RYTARY ER 36.25 MG-145 MG capsules. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of July 19, 2024. The contract does not have a set-aside designation, indicating it was open to full and open competition. AmerisourceBergen holds a...
This federal contract award, valued at $1,979.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of RYTARY ER 61.25 MG-245 MG CAP 100S, a pharmaceutical product, over the period ending on April 29, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...
This federal contract award, valued at $2,489.10, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RYTARY ER 48.75 MG-195 MG capsules, a medication used in the treatment of Parkinson's disease. The award is a Firm Fixed Price Delivery Order with a period of performance through July 5, 2024. It is not associated with any set-aside requirements....
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB23FP8L2
    Delivery Order

This federal contract award, valued at $2,161.30, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under the existing Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The specific award is for RYTARY ER 36.25 MG-145 MG capsules, a medication used for the treatment of Parkinson's disease. There is no set-aside designation for this contract, indicating open competition. The contract has a period of performance through September 25, 2023.

Generated 5/12/25, 10:03 AM